Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Evaluation of Absorb BVS, the Bioresorbable Vascular Scaffold, in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Chinese Population

Trial Profile

A Clinical Evaluation of Absorb BVS, the Bioresorbable Vascular Scaffold, in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Chinese Population

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2018

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms ABSORB China
  • Sponsors Abbott Vascular
  • Most Recent Events

    • 25 Sep 2018 Results assessing 4-year clinical outcomes, presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
    • 25 Sep 2018 Results reporting influence of procedural technique on Everolimus-Eluting Stent outcomes within the ABSORB trials (ABSORB II, ABSORB III, ABSORB China and ABSORB Japan) presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
    • 28 Jan 2016 According to an Abbott media release, results from this trial were presented at the Transcatheter Cardiovascular Therapeutics conference in October 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top